Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Therapeutical antibodies > lambrolizumab

lambrolizumab

Monday 3 June 2013

MK-3475

WP

Lambrolizumab (also known as MK-3475) is a drug in development by Merck that targets the PD-1 receptor. The drug is intended for use in treating metastatic melanoma.